Overview

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Status:
Completed

Trial end date:
2018-07-19

Target enrollment:

Participant gender:

Summary

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Analytical Laboratory (Pharmacokinetic Sample Analysis): USA
Clinical Laboratory: USA
Contract Research Organization: USA
Covance Bioanalytical Services, LLC
GenX Laboratories Inc.
Harbor Hospital Laboratory
PAREXEL Early Phase Clinical Unit Baltimore
PAREXEL Early Phase Clinical Unit-Los Angeles

Treatments:

Dapagliflozin
Febuxostat
Uric Acid
Verinurad